ライフサイエンスコーパス: nucleoside

1 -H), a sulfur-containing analog of a natural nucleoside.

2 h the terminal adenosine and the penultimate nucleoside.

3 a nucleoside in genomic DNA with a modified nucleoside.

4 ect or incorrect incorporation opposite this nucleoside.

5 cision of most atoms of a specific guanosine nucleoside.

6 modeling and docking of these hypermodified nucleosides.

7 low the de novo synthesis of amino acids and nucleosides.

8 iester bonds linking adjacent threofuranosyl nucleosides.

9 s in the conformational preferences of these nucleosides.

10 e the silencing activity when placed between nucleosides 10 and 12, at the catalytic site of Argonaut

11 riboswitch class that most tightly bind the nucleoside 2'-deoxyguanosine.

12 nucleosides that can be readily converted to nucleoside 2'-phosphoramidites or 3'-triphosphates for s

13 ase that increases the cytoplasmic levels of nucleoside 3',5'-cyclic monophosphates (cNMPs) to mediat

14 thod for synthesizing alpha-l-threofuranosyl nucleoside 3'-monophosphates (tNMPs), 3'-phosphoro(2-met

15 base surrogates, 2-thienyl-3-hydroxychromone nucleoside (3HCnt) and thienoguanosine ((th)G), incorpor

16 icantly by coadministration of an artificial nucleoside (5-nitroindolyl-2'-deoxyriboside, 5-NIdR) tha

17 Traditionally, enzymatic synthesis of nucleoside-5'-monophosphates (5'-NMPs) using low water-s

18 transporters (ENTs) translocate hydrophilic nucleosides across cellular membranes and are essential

19 Adenine nucleotides and nucleosides act on purinoceptors on cardiomyocytes, AV a

20 ne diphosphate, adenosine monophosphate) and nucleoside (adenosine and inosine) levels were quantifie

21 Tide approach applied to a series of acyclic nucleosides aimed at the identification of novel and sel

22 hnique to label HIV-1 genomes using modified nucleosides, allowing subsequent imaging of cytoplasmic

23 f 5'-mono-, 5'-di-, and 5'-triphosphorylated nucleosides, also known as nucleotides, as well as sever

24 sses of compounds (peptides, catecholamines, nucleosides, amino acids, etc.).

25 ucleoside kinase pathway activity, we used a nucleoside analog 2'3'-dideoxycytidine (ddC), which is p

26 tiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, provid

27 The nucleoside analog cytarabine (Ara-C) is an essential com

28 Furthermore, as the nucleoside analog ganciclovir is the current drug of cho

29 propyl)adenine (DHPA), a plausibly prebiotic nucleoside analog of adenosine.

30 5-Azacytidine (AZA) is a nucleoside analog that is used to treat preleukemic and

31 4 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a

32 e more activated, which can be normalized by nucleoside analog therapy.

33 s compound, 6-ethylthioinosine (6-ETI), is a nucleoside analog with toxicity to PEL in vitro and in v

34 lated that SAMHD1 sensitizes cancer cells to nucleoside-analog derivatives through the depletion of c

35 very, from microbial-extract screening, of a nucleoside-analog inhibitor that inhibits bacterial RNA

36 Several nucleoside analogs are effective in treating leukemias a

37 exible preparation of three classes of these nucleoside analogs from common precursors-properly subst

38 nt virus was more resistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the

39 plex virus is a major pathogen, and although nucleoside analogs such as acyclovir are highly effectiv

40 Nucleoside analogs such as gemcitabine diphosphate and c

41 or parasite and LRV1 inhibition, focusing on nucleoside analogs to capitalize on the highly active sa

42 n wild-type enzyme and a mutant resistant to nucleoside analogs used to treat HIV infections reveal t

43 The desired 5'-O-DMT-protected nucleoside analogs were synthesized from suitably protec

44 side effects commonly seen with conventional nucleoside analogs.

45 nes also led to an increased response to the nucleoside analogue 5-fluorouracil, suggesting that lowe

46 tients receiving treatment with the cytidine nucleoside analogue cytarabine.

47 Giving the mice the nucleoside analogue entecavir reduced viral loads and de

48 for the efficient intracellular delivery of nucleoside analogue monophosphates and monophosphonates.

49 Retreatment with a purine nucleoside analogue often leads to an effective but limi

50 According to specific guidelines, nucleoside analogue prophylaxis is recommended in anti-H

51 Several nucleoside analogue RTIs (NRTIs) blocked K103 RT activit

52 ex formation is the greatest of any reported nucleoside analogue that can participate in Watson-Crick

53 ignificant efforts have been made to develop nucleoside analogues adopting specific conformations to

54 perties of tenofovir (TFV) and other charged nucleoside analogues are dramatically improved upon conj

55 Most fluorescent nucleoside analogues are quenched when base stacked and

56 survival across multiple cancer types where nucleoside analogues are used in cancer treatment.

57 A series of nucleoside analogues bearing a 1,4,5-trisubstituted-1,2,

58 Nucleoside analogues bearing a fluorine in the C2'-posit

59 atural component of RNA, and various other C-nucleoside analogues have been reported previously for t

60 e has been little progress toward developing nucleoside analogues that markedly increase their fluore

61 EFV to RAL (400 mg twice daily), maintaining nucleoside analogues unchanged, or to continue with EFV

62 Acyclic nucleoside analogues used in this study were identified

63 The first C-nucleoside analogues were described about half a century

64 The novel nucleoside analogues were incorporated into oligonucleot

65 Nucleodyes, visibly colored chromophoric nucleoside analogues, are reported.

66 Two new C-nucleoside analogues, BCX4430, an imino-C-nucleoside, an

67 In this Perspective, we demonstrate that nucleoside analogues, cornerstones of anticancer and ant

68 s, indenoisoquinolines and cisplatin but not nucleoside analogues.

69 y liver disease (NAFLD) receiving EFV plus 2 nucleoside analogues.

70 es unchanged, or to continue with EFV plus 2 nucleoside analogues.

71 TN cells were largely involved in nitrogen, nucleoside and amino acid metabolisms.

72 deoxynucleoside triphosphates into component nucleoside and inorganic triphosphate.

73 nally, the emissive features of the modified nucleoside and its responsiveness to environmental chang

74 l development for enzyme characterization or nucleoside and non-nucleoside inhibitor screening in a h

75 he/454), and the sequences were screened for nucleoside and nonnucleoside RT inhibitor DRM.

76 Regulation of this process is maintained by nucleoside and nucleotide transporters, as well as the e

77 kflow by correctly identifying 10 methylated nucleosides and 6 methylated amino acids.

78 detection in the range of 14-53ngmL(-1) for nucleosides and 7-23, 20-49 and 64-124ngmL(-1) for nucle

79 gent substrate selectivity toward endogenous nucleosides and clinically used nucleoside drugs.

80 It would be worth revisiting these C-nucleosides and derivatives thereof, including their pho

81 To explore the interaction of nucleosides and nucleobases in the context of the Mailla

82 the simultaneous determination of unmodified nucleosides and nucleotide mono-, di- and tri-phosphates

83 icient method for the joint determination of nucleosides and nucleotides in dairy and non-dairy baby

84 e and ribose-5-phosphate in water to produce nucleosides and nucleotides in good yields.

85 m (trophic) actions of purine and pyrimidine nucleosides and nucleotides promote migration and prolif

86 labeling enrichment differences into the DNA nucleosides and their isotopologues (e.g. deoxyadenosine

87 This highlights the potential of modified nucleosides and their phosphate prodrugs as treatments f

88 all molecules including polyphenols, amides, nucleosides and their precursors, the development of mac

89 C-nucleoside analogues, BCX4430, an imino-C-nucleoside, and GS-6620, a phosphoramidate derivative of

90 nitude lower than the corresponding parental nucleosides, and as low as 23.01 femtograms, 64.09 attom

91 g blocks of nucleic acids (i.e. nucleobases, nucleosides, and nucleotides) are desirable candidates f

92 (amino acids, peptides, sugars, nucleobases, nucleosides, and nucleotides).

93 Herbicidins are adenosine-based nucleoside antibiotics with an unusual tricyclic undecos

94 m(6)A nucleosides are abundant in ZIKV RNA, with twelve m(6)A

95 ating cyclic dinucleotides whose constituent nucleosides are adenosine and inosine and that vary by r

96 C-Nucleosides are an underexplored and important class of

97 Carbocyclic C-nucleosides are quite rare.

98 otide strategies has expanded the utility of nucleosides as a therapeutic class.

99 Nucleoside-based cofactors are presumed to have preceded

100 ein folds, and most Rossmann enzymes utilize nucleoside-based cofactors.

101 important to evaluate the photogeneration of nucleoside-based radicals in nonaqueous media.

102 Similarly, nucleoside-based therapeutics may adopt different confor

103 ctive site, which lead to the formation of a nucleoside-binding pocket and a peptide-binding site.

104 Acyclic nucleoside bisphosphonates (ANbPs) have previously been

105 llowed by MS(2) scans to screen for modified nucleosides by coeluting peaks containing precursor and

106 It preferred nucleosides compared with nucleobases.

107 Acyclic nucleosides containing a 3-fluoro-2-(phosphonomethoxy)pr

108 harmacokinetic profiles of the corresponding nucleoside-containing drugs.

109 The free amino acid and 5'-nucleotide/nucleoside contents of studied species differed from eac

110 The discovery and optimization of non-nucleoside dengue viral RNA-dependent-RNA polymerase (Rd

111 tion of electronic excited states of the DNA nucleoside deoxycytidine (dCyd) and its methylated analo

112 cent quantum yield as compared with the free nucleoside, depending on neighboring bases.

113 GLS1 inhibitor-induced nucleoside depletion and ROS enhancement led to DNA repl

114 the heart and regiospecific distributions of nucleoside derivatives and eicosanoids, which we correla

115 dified (N)-methanocarba 5'-N-methyluronamide nucleoside derivatives with regard to their ability to m

116 -MECA, (N)-methanocarba 5'-N-methyluronamide nucleoside derivatives with significant N(6) or C2 modif

117 escribe a novel stereoselective synthesis of nucleoside derivatives with the ribose ring locked in th

118 at the third codon position, the methylated nucleosides did not compromise the speed or accuracy of

119 Recently, the nucleoside diphosphate hydrolase NUDT15 has received att

120 ggest that the deregulation of mitochondrial nucleoside diphosphate kinase (NDPK) together with defec

121 dephosphorylates the catalytic histidine on nucleoside diphosphate kinase B (NDPK-B).

122 creasing pancreatic Zn(2+) (hZnT8WT) induced nucleoside diphosphate kinase B, and Zn(2+) reduction (h

123 th in host cells, an effect regulated by the nucleoside diphosphate kinase ndk-1.

124 sidue (His358) in the cytoplasmic region, by nucleoside diphosphate kinase-B (NDPK-B).

125 Nucleoside diphosphate kinases (NDKs) play a central rol

126 Nucleoside diphosphate kinases (NDPKs) are enriched at t

127 loop 2) to regulate RR specificity among its nucleoside diphosphate substrates.

128 Nucleoside-diphosphate-kinases (NDKs) are leaderless, mu

129 lin and, surprisingly, can instead hydrolyze nucleoside diphosphates and triphosphates, which may pla

130 est rate observed for the rearrangement of a nucleoside directly at the binding site and the smallest

131 d to a pyrrole ring, and their corresponding nucleosides display a broad applicability in medicinal c

132 (hNTs) mediate cellular influx of anticancer nucleoside drugs, including cytarabine, cladribine, and

133 d endogenous nucleosides and clinically used nucleoside drugs.

134 yme hydrolysis to release the cross-links as nucleosides, enrichment by a reversed-phase solid-phase

135 n agents, HBV release inhibitors, anti-sense nucleosides, exogenous interferon stimulation, interfero

136 A requires proper positioning of the nick 3' nucleoside for catalysis of 5' adenylylation; and (ii) E

137 accesses beta-2-thioribouridine, a modified nucleoside found in transfer RNA that enables both faste

138 Most nucleosides (from both isomeric series) exerted low micr

139 ce, it must first separate the phosphate and nucleoside groups before transporting phosphate into the

140 Post-transcriptional modification of RNA nucleosides has been implicated as a pivotal regulator o

141 ugh an efficient method for synthesizing TNA nucleosides has been reported, very few advances have be

142 Purine nucleosides have smaller EE values with opposite sign to

143 ano-2'-C-methyl-4-aza-7,9-dideazaadenosine C-nucleoside, have been recently described as effective ag

144 Pan-genotypic nucleoside HCV inhibitors display a high genetic barrier

145 ydrolysis in cda mutants is likely caused by NUCLEOSIDE HYDROLASE1 (NSH1) because cytosine accumulati

146 Sugar puckering of nucleosides impacts nucleic acid structures; hence their

147 es of replacing a large fraction or all of a nucleoside in genomic DNA with a modified nucleoside.

148 ed for the quantification of nucleotides and nucleosides in sixteen samples of commercial baby foods.

149 rmational preferences of chemically modified nucleosides in solution.

150 can interpret MS/MS data containing modified nucleosides in two modes: fixed and variable.

151 uki-Miyaura cross-coupling of four different nucleosides in water under mild conditions.

152 nzyme characterization or nucleoside and non-nucleoside inhibitor screening in a high-throughput mann

153 have been solved showing small molecule non-nucleoside inhibitors bound to the hepatitis C viral pol

154 ibitors and in 16 patients the C316N/Y/H non-nucleoside inhibitors were found mainly in liver samples

155 new antibiotics, as many naturally occurring nucleoside inhibitors with antibacterial activity target

156 g chronic systemic treatment with the purine nucleoside inosine.

157 Thus, AML cells have increased cytidine nucleoside kinase activity that regulates mtDNA biogenes

158 To assess cytoplasmic nucleoside kinase pathway activity, we used a nucleoside

159 Knockdown of cytoplasmic nucleoside kinases reduced mtDNA levels in AML cells, de

160 ide transporters and a subset of cytoplasmic nucleoside kinases, were also increased in AML compared

161 -dideoxycytidine triphosphate by cytoplasmic nucleoside kinases.

162 nd did not affect total renal nucleotide and nucleoside levels during ischemia.

163 rom lipid, amino acid, neurotransmitter, and nucleoside metabolism are attached.

164 bohydrolase NSH1, linking AtRBSK activity to nucleoside metabolism.

165 douridine (N1mPsi) outperforms several other nucleoside modifications and their combinations in terms

166 ization with lipid-nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) encoding the pre-mem

167 ravenous HIV-1 challenge, demonstrating that nucleoside-modified mRNA represents a viable delivery pl

168 These data demonstrate that nucleoside-modified mRNA-LNP elicits rapid and durable p

169 o expression of therapeutic antibodies using nucleoside-modified mRNA.

170 nstrate feasibility and protective efficacy, nucleoside-modified mRNAs encoding the light and heavy c

171 Immunization with 30 mug of nucleoside-modified ZIKV mRNA-LNP protected mice against

172 It started from the masking of nucleoside monophosphate and monophosphonate groups by s

173 cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species.

174 The approval of sofosbuvir, a nucleoside monophosphate prodrug, highlighted the succes

175 Nucleoside monophosphates and monophosphonates have been

176 Increased levels of tRNA-specific modified nucleosides (N2,N2-dimethylguanosine, N1-methylinosine),

177 Nucleoside, nucleotide, and base analogs have been in th

178 Nucleoside/nucleotide RT inhibitor mutations were found

179 and hydrogels formed through the assembly of nucleosides, nucleotides, and their derivatives.

180 but the beta phosphate and the nicotinamide nucleoside of the nicotinamide mononucleotide (NMN) leav

181 phosphate opposite the 5'-A, the 3'-terminal nucleoside of the primer was disordered, consistent with

182 inhibitors (INSTIs) coadministered with two nucleoside or nucleotide reverse transcriptase inhibitor

183 be inhibited directly through the action of nucleosides or nucleotide analogues or allosterically at

184 Suzuki-Miyaura crosscoupling of halogenated nucleosides or nucleotides with 4-(trifluoroacetyl)pheny

185 In addition to the canonical nucleosides, our synthesis accesses beta-2-thioribouridi

186 hat adenine, diaminopurine, and hypoxanthine nucleoside phosphates and a noncanonical pyrimidine nucl

187 (NPP) family, the members of which hydrolyze nucleoside phosphates, phospholipids, and other related

188 ed and evaluated several alkoxyalkyl acyclic nucleoside phosphonate diesters and identified octadecyl

189 The synthesis of four l-2'-deoxy-threose nucleoside phosphonates with the natural nucleobases ade

190 rd the synthesis of other types of 3'-fluoro nucleoside phosphonates.

191 sition path sampling study with heavy purine nucleoside phosphorylase (PNP) characterized the experim

192 Purine nucleoside phosphorylase (PNP) is part of the human puri

193 upling at the catalytic site of human purine nucleoside phosphorylase (PNP).

194 tment using sofosbuvir, ledipasvir and a non-nucleoside polymerase-inhibitor (GS-9669) or a protease-

195 ave been synthesized along with the quencher nucleosides possessing 6-{4-[(4-dimethylamino)azo]phenyl

196 selection in HBV DNA and increased A3G's 5' nucleoside preference for deoxycytidine (5'-CC).

197 Uridine, a pyrimidine nucleoside present at high levels in the plasma of roden

198 Taken together, our nucleoside probe represents a new class of biophysical t

199 cribe the first example of a multifunctional nucleoside probe, containing a conformation-sensitive fl

200 n from the nitrogen-hydrogen bonds in purine nucleosides produces reactive intermediates that are imp

201 nts on (N)-methanocarba 5'-N-methyluronamide nucleosides promote a progressive outward shift of the A

202 The C-nucleoside pseudouridine is a natural component of RNA,

203 Whereas treatment with the nucleoside purine analogues cladribine and pentostatin r

204 rsion of a triphosphorylated compound into a nucleoside, releasing one molecule of inorganic phosphat

205 efavirenz, nevirapine, and lamivudine, with nucleoside resistance including type 2 thymidine analog

206 T1 and hCNT2 transport pyrimidine and purine nucleosides, respectively, whereas hCNT3 transports both

207 The clinical benefits of HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs

208 Nucleoside reverse transcriptase (RT) inhibitors (NRTIs)

209 NRTI, mainly abacavir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3

210 gue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevir

211 BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) design

212 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has bee

213 troviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

214 als, particularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior

215 We found similar proportions of overall and nucleoside reverse transcriptase inhibitor-associated mi

216 One participant in the atazanavir group had nucleoside reverse transcriptase inhibitor-associated re

217 ithout 12-weekly CD4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, main

218 e more common for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and p

219 were on two ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or rit

220 erse-transcriptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and

221 antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) mig

222 The prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) rea

223 d identification of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) wit

224 mal initial regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus

225 Nucleoside reverse transcriptase inhibitors (NRTIs) with

226 inhibitors in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integras

227 were not observed with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying

228 8.8% having resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectivel

229 s of initial antiretroviral therapy with two nucleoside reverse transcriptase inhibitors.

230 se Inhibitors (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

231 is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resis

232 T) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in s

233 ver the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) seco

234 1 strains to 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 n

235 was reduced in plants also deficient in the nucleoside ribohydrolase NSH1, linking AtRBSK activity t

236 s to efficient trapping of population in the nucleoside's excited triplet state in high yield.

237 otein-coupled receptor modeling to repurpose nucleoside scaffolds in favor of binding at nonpurine re

238 These characteristics make nucleoside self-assembly on a substrate an attractive ap

239 Only the 8-phenyl nucleoside shows strong fluorescence in polar aprotic so

240 We observed that nucleosides significantly alleviated RSV-induced replica

241 nd alleviation of replication stress through nucleoside supplementation.

242 proach using these two different fluorescent nucleoside surrogates advances the mechanistic understan

243 to generate using the standard approach for nucleoside synthesis.

244 oma with temozolomide and a novel artificial nucleoside that inhibits replication of damaged DNA can

245 ormation of the C4' radical of the guanosine nucleoside that is subsequently excised.

246 e smallest rate observed for the 3'-unpaired nucleoside that stacks onto the pseudo-knot-closing Wats

247 for constructing multigram quantities of TNA nucleosides that can be readily converted to nucleoside

248 nofovir (TFV), adefovir, and other antiviral nucleosides that demonstrate potent antiviral activity b

249 f phosphorus-stereogenic phosphoramidates to nucleosides through a dynamic stereoselective process.

250 variety of (pre)biological building blocks (nucleosides/tides, amino acids and lipid precursors) und

251 modification is the conversion of adenosine nucleosides to inosine (A-to-I), mediated by the ADAR fa

252 ivity of 2'-O-methylated and 2'-hydroxylated nucleosides to periodate oxidation to develop Nm-seq, a

253 NT1 and hENT2, which mediate plasma membrane nucleoside transport at pH 7.4, hENT3 is an acidic pH-ac

254 mechanistic basis of acidic pH-driven hENT3 nucleoside transport with site-directed mutagenesis, hom

255 The human SLC28 family of concentrative nucleoside transporter (CNT) proteins has three members:

256 Erythrocyte equilibrative nucleoside transporter 1 (eENT1) levels are reduced in h

257 They import purines via equilibrative nucleoside transporter 1 (ENT1) homologs.

258 e of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to

259 xin43, connexin37, pannexin-1, equilibrative nucleoside transporter 1, CD39, CD73, ecto-nucleotide py

260 f vesicles containing SGLT1 or concentrative nucleoside transporter 1.

261 and outward-facing states of a concentrative nucleoside transporter from Neisseria wadsworthii.

262 ighly sensitive to inhibition by the classic nucleoside transporter inhibitors dipyridamole and nitro

263 Equilibrative nucleoside transporters (ENTs) translocate hydrophilic n

264 Human nucleoside transporters (hNTs) mediate cellular influx o

265 ve epithelial differentiation, expression of nucleoside transporters affecting gemcitabine response,

266 se models with dipyridamole, an inhibitor of nucleoside transporters that potentiates extracellular a

267 tance is reduced uptake into tumor cells via nucleoside transporters, although precise mechanisms are

268 Viral loss was specific to antiviral nucleoside treatment and not induced by growth inhibitor

269 Nucleoside tri-phosphates (NTP) form an important class

270 ain-containing protein 1 (ELMOD1), a guanine nucleoside triphosphatase activating protein (GAP) for A

271 The pharmacologically active nucleoside triphosphate (NTP) is efficiently formed in m

272 tion, switching residues, and catalysis make nucleoside triphosphate hydrolysis conditional on domain

273 ggesting that the viperin substrate may be a nucleoside triphosphate of some type.

274 rmational changes in motifs B and D, and the nucleoside triphosphate reorientation represent separabl

275 ain of Escherichia coli that, by virtue of a nucleoside triphosphate transporter from Phaeodactylum t

276 ersion of this compound to the corresponding nucleoside triphosphate, 5-nitroindolyl-2'-deoxyriboside

277 the catabolism of canonical and noncanonical nucleoside triphosphates (dNTPs) and has been associated

278 (SSO) that imports the constituent unnatural nucleoside triphosphates and uses them to replicate DNA

279 ription in the presence of (th) G and native nucleoside triphosphates enforces initiation with the un

280 The modified nucleoside triphosphates were good substrates for DNA po

281 lar, deamination of adenine moiety in (deoxy)nucleoside triphosphates, resulting in formation of (d)I

282 mplicated ones are envisioned if two or more nucleoside types are combined.

283 Resistance to xenobiotic nucleosides used to treat acute myeloid leukemia (AML) a

284 hCNT3 transports both pyrimidine and purine nucleosides utilizing Na(+) and/or H(+) electrochemical

285 on of a canonical nucleoside with a modified nucleoside, we previously replaced around 75% of thymidi

286 ination with feeding of isotopically labeled nucleosides, we were able to trace the intermediates bac

287 Free amino acids, 5'-nucleotides and nucleosides were analyzed from four Nordic forest mushro

288 The nucleosides were converted to 5'-O-mono-(dA(SR)MP) or tr

289 V-1 at low micromolar range while the parent nucleosides were not effective.

290 odified thymidine, LNA-T, and 2'-amino-LNA-T nucleosides were synthesized, converted into the corresp

291 activity was identified when 2'-C-methylated nucleosides were tested, suggesting that these compounds

292 ated EE has the same sign for all pyrimidine nucleosides which is opposite to that for amino-acids.

293 urotransmitter transporter activity of rigid nucleosides while reducing A3AR affinity.

294 reased susceptibility to tenofovir and other nucleosides, while reversion of the T69del showed increa

295 We also developed the synthesis of these two nucleosides whose N(7) side chains are protected by TBS

296 of replacing a large fraction of a canonical nucleoside with a modified nucleoside, we previously rep

297 are an underexplored and important class of nucleosides with antiviral and anticancer activity.

298 The typical approach for analyzing modified nucleosides within RNA sequences by mass spectrometry in

299 Sulfur is present in several nucleosides within tRNAs.

300 ide phosphates and a noncanonical pyrimidine nucleoside (zebularine) phosphate can be formed from the